FibroGen (FGEN) Downgraded to “Sell” at BidaskClub
BidaskClub cut shares of FibroGen (NASDAQ:FGEN) from a hold rating to a sell rating in a research note issued to investors on Thursday.
Other equities analysts also recently issued research reports about the company. Stifel Nicolaus restated a buy rating and issued a $80.00 price objective on shares of FibroGen in a report on Thursday, September 14th. Jefferies Group restated a buy rating and issued a $75.00 price objective on shares of FibroGen in a report on Tuesday, September 12th. Mizuho restated a hold rating and issued a $61.00 price objective on shares of FibroGen in a report on Thursday, November 9th. William Blair restated an outperform rating on shares of FibroGen in a report on Wednesday, August 9th. Finally, ValuEngine downgraded FibroGen from a hold rating to a sell rating in a report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. FibroGen has an average rating of Buy and a consensus price target of $65.67.
Shares of FibroGen (NASDAQ FGEN) traded up $1.15 on Thursday, hitting $46.40. The stock had a trading volume of 662,827 shares, compared to its average volume of 617,430. FibroGen has a one year low of $19.25 and a one year high of $60.15. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.83 and a current ratio of 10.83.
Several institutional investors and hedge funds have recently bought and sold shares of FGEN. FMR LLC boosted its position in shares of FibroGen by 96.9% in the second quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock valued at $107,753,000 after acquiring an additional 1,641,423 shares during the period. EcoR1 Capital LLC boosted its position in shares of FibroGen by 3,674.1% in the second quarter. EcoR1 Capital LLC now owns 1,585,457 shares of the biopharmaceutical company’s stock valued at $51,210,000 after acquiring an additional 1,543,448 shares during the period. Janus Henderson Group PLC bought a new stake in shares of FibroGen in the second quarter valued at approximately $45,633,000. Eagle Asset Management Inc. bought a new stake in shares of FibroGen in the third quarter valued at approximately $46,158,000. Finally, Vanguard Group Inc. boosted its position in shares of FibroGen by 15.1% in the second quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock valued at $187,612,000 after acquiring an additional 761,421 shares during the period. 57.42% of the stock is owned by institutional investors.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.